Vivani Medical Inc. (VANI)

In the past six months, Vivani Medical, Inc.'s stock price has been impacted by several events. The company reported its fourth quarter and full-year 2025 financial results on March 26, 2026, and third-quarter 2025 results on November 13, 2025. Vivani Medical announced the pricing and closing of common stock offerings in January 2026 and October 2025, and a $10 million equity financing in August 2025. The successful completion of the LIBERATE-1 first-in-human study and positive preclinical proof-of-concept data for the NPM-139 semaglutide implant have been significant catalysts. As of early April 2026, the stock has decreased by 18.70% in the past month and 1.96% over the last 12 months.

As a clinical-stage biopharmaceutical company, Vivani Medical, Inc. currently has no product revenues. Its business growth is primarily dependent on the successful clinical execution and eventual commercialization of its drug implants. While there is no current demand seasonality for its products or services, the global GLP-1 obesity market, which Vivani Medical aims to enter, is projected to experience significant growth, exceeding USD 48 billion by 2030.

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative, long-term drug implants for chronic diseases, utilizing its NanoPortal™ platform technology to create miniature, subdermal drug implants designed to deliver medication steadily over extended periods, improving medication adherence and tolerability. The company's primary product pipeline is centered on GLP-1 implants for metabolic diseases, including NPM-115 for chronic weight management, NPM-119 for type 2 diabetes, NPM-139 for chronic weight management/obesity, and OKV-119 for metabolic diseases in cats. Vivani Medical also has a subsidiary, Cortigent, Inc., which is developing targeted neurostimulation systems.

Vivani Medical, Inc. is headquartered in Alameda, California, United States. The company serves a customer base across the United States and has established distribution partnerships to extend its reach into select European and Latin American markets.

In the past year, Vivani Medical, Inc. has maintained a generally positive brand reputation, as indicated by a news sentiment score of 0.90, which is higher than the average for medical companies. There have been no specific negative events reported that have significantly impacted the company's reputation. News coverage and search interest for Vivani Medical are relatively low.

Vivani Medical, Inc. has a diverse ownership structure. Institutional investors hold approximately 1.52% to 5.61% of the company's stock, while insiders own a substantial portion, ranging from approximately 56.36% to 184.67%. Retail and individual investors hold around 38.03%. Major institutional owners include Vanguard Group Inc, Tudor Investment Corp Et Al, Tanager Wealth Management LLP, Geode Capital Management, Llc, Commonwealth Equity Services, Llc, BlackRock, Inc., Monetary Management Group Inc, State Street Corp, Susquehanna International Group, Llp, and Marshall Wace, Llp. Gregg Williams is identified as the largest individual shareholder.